Trial Profile
A Randomised, Double-blind, Double-dummy, Three-period Cross-over Trial to Compare Post Prandial Blood Glucose Control of BioChaperone Combo With Humalog Mix25 and With Simultaneous Injections of Humalog and Lantus in Subjects With Type 2 Diabetes
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin glargine/insulin lispro (Primary) ; Insulin glargine; Insulin lispro; Insulin neutral protamine lispro/insulin lispro
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Adocia
- 05 Oct 2018 Results presented at the 54th Annual Meeting of the European Association for the Study of Diabetes
- 28 Jun 2017 Status changed from recruiting to completed.
- 06 Jun 2017 Primary endpoint (Delta AUC BG 0-2h (area under the blood glucose concentration-time curve)) has been met according to an Adocia media release.